BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Theys C, Lauwers D, Perez-novo C, Vanden Berghe W. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs? Biomedicines 2022;10:3041. [DOI: 10.3390/biomedicines10123041] [Reference Citation Analysis]
2 Salavatizadeh M, Soltanieh S, Poustchi H, Yari Z, Shabanpur M, Mansour A, Khamseh ME, Alaei-shahmiri F, Hekmatdoost A. Dietary total antioxidant capacity is inversely associated with the odds of non-alcoholic fatty liver disease in people with type-2 diabetes. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1037851] [Reference Citation Analysis]
3 Wang J, Chu H, Wang Z, Wang X, Liu X, Song Z, Liu F. In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ). Cell Oncol 2022. [DOI: 10.1007/s13402-022-00733-1] [Reference Citation Analysis]
4 Ortiz-lópez N, Fuenzalida C, Dufeu MS, Pinto-león A, Escobar A, Poniachik J, Roblero JP, Valenzuela-pérez L, Beltrán CJ. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 2022;13:954869. [DOI: 10.3389/fimmu.2022.954869] [Reference Citation Analysis]
5 Lai M, De Carli A, Filipponi C, Iacono E, La Rocca V, Lottini G, Piazza CR, Quaranta P, Sidoti M, Pistello M, Freer G. Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes. Antiviral Res 2022;206:105398. [PMID: 35985406 DOI: 10.1016/j.antiviral.2022.105398] [Reference Citation Analysis]
6 Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12:824. [PMID: 35740949 DOI: 10.3390/biom12060824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Fedchenko T, Izmailova O, Shynkevych V, Shlykova O, Kaidashev I, Mandard S. PPAR-γ Agonist Pioglitazone Restored Mouse Liver mRNA Expression of Clock Genes and Inflammation-Related Genes Disrupted by Reversed Feeding. PPAR Research 2022;2022:1-16. [DOI: 10.1155/2022/7537210] [Reference Citation Analysis]